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A prolonged run-in period 
of standard subcutaneous 
microdialysis ameliorates quality 
of interstitial glucose signal in 
patients after major cardiac surgery
Othmar Moser1,2,3, Julia Münzker1, Stefan Korsatko1, Christoph Pachler4, Karlheinz Smolle5, 
Wolfgang Toller6, Thomas Augustin7, Johannes Plank8, Thomas R. Pieber1,7, Julia K. Mader  1 
& Martin Ellmerer1
We evaluated a standard subcutaneous microdialysis technique for glucose monitoring in two 
critically ill patient populations and tested whether a prolonged run-in period improves the quality 
of the interstitial glucose signal. 20 surgical patients after major cardiac surgery (APACHE II score: 
10.1 ± 3.2) and 10 medical patients with severe sepsis (APACHE II score: 31.1 ± 4.3) were included 
in this investigation. A microdialysis catheter was inserted in the subcutaneous adipose tissue of the 
abdominal region. Interstitial fluid and arterial blood were sampled in hourly intervals to analyse 
glucose concentrations. Subcutaneous adipose tissue glucose was prospectively calibrated to 
reference arterial blood either at hour 1 or at hour 6. Median absolute relative difference of glucose 
(MARD), calibrated at hour 6 (6.2 (2.6; 12.4) %) versus hour 1 (9.9 (4.2; 17.9) %) after catheter insertion 
indicated a significant improvement in signal quality in patients after major cardiac surgery (p < 0.001). 
Prolonged run-in period revealed no significant improvement in patients with severe sepsis, but the 
number of extreme deviations from the blood plasma values could be reduced. Improved concurrence 
of glucose readings via a 6-hour run-in period could only be achieved in patients after major cardiac 
surgery.
In recent years, clinical management of glycaemia in critically ill patients has tremendously changed. Glucose 
levels within a low- normal range were shown to be associated with prolonged hospital stay and increased risk 
of death1. In addition to life-threatening low glucose levels and hypoglycaemia, hyperglycaemia was found 
to be associated with a rise in morbidity due to infections and higher incidence of post-surgical infections2. 
Intriguingly, mild hyperglycaemia with 7.8–10 mmol/l reduced both the rate of morbidity and mortality in a 
greater extent than strict euglycaemia (4.5–6 mmol/l) in different groups of critically ill patients. Evidence sug-
gests that near-normal target ranges (7.2 – 8 mmol/l) are safe and do also translate to lower mortality. To achieve 
these goals, glucose concentration should be measured by repeated arterial measurements using a blood gas 
analyser - the gold standard in critical care3. Regular blood glucose testing on the other hand is associated with 
1Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, 
Austria. 2Diabetes Research Group, School of Medicine, Swansea University, Swansea, United Kingdom. 3Applied 
Sport, Technology, Exercise and Medicine Research Centre (A-STEM), College of Engineering, Swansea University, 
Swansea, United Kingdom. 4Department of Cardiology and Intensive Care Medicine, LKH Graz Süd-West, 
Graz, Austria. 5Intensive Care Unit, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 
6Department of Anaesthesiology, Medical University of Graz, Graz, Austria. 7Institute for Biomedicine and Health 
Sciences, Joanneum Research GmbH, HEALTH, Graz, Austria. 8Division of Gastroenterology and Hepatology, 
Department of Internal Medicine, Medical University of Graz, Graz, Austria. Othmar Moser and Julia Münzker 
contributed equally to this work. Correspondence and requests for materials should be addressed to J.K.M. (email: 
julia.mader@medunigraz.at)
Received: 4 July 2017
Accepted: 8 January 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIEnTIfIC REPORTs |  (2018) 8:1262  | DOI:10.1038/s41598-018-19768-2
increased workload for nursing staff and might reduce adherence to established protocols aiming for euglycaemia 
and reduced glucose variability4.
Alternative methods for glucose determination which decrease the workload for nursing staff could overcome 
these issues. Continuous subcutaneous glucose monitoring either by using commercially available continuous 
monitoring (CGM) systems5–9 or by means of standard microdialysis10–13 has been proven to accurately track 
changes in glucose concentration in both patients with type 1 and type 2 diabetes mellitus. Not only acute also 
long long-term clinical outcomes were found to be improved when using CGM systems. In a recent analysis 
within the T1D Exchange clinic registry, glycaemic control was significantly ameliorated in patients using CGM 
than those who did self-monitoring of blood glucose (SMBG), regardless of using an insulin pump or multiple 
daily injections via insulin pen14.
One of the remaining challenges in CGM is system calibration which should be performed at an optimal time 
point (i.e. during stable glycaemia) to allow for sufficient accuracy of the CGM signal. A reliable CGM system 
could help monitoring changes in glycaemia in a higher resolution, thus preventing life-threatening hypo- and 
hyperglycaemic episodes.
Venous microdialysis was shown to be a highly accurate and reliable method for continuous blood glucose 
monitoring up to 48 hours in patients undergoing cardiac surgery in intensive care units (ICU)15, but if the subcu-
taneous tissue is also a reliable spot for glucose measurement has not been finally proven. In patients undergoing 
cardiac surgery it was found that subcutaneous CGM systems repeatedly underestimated glucose values, which 
was not supposed to be linked to impaired microcirculation8. In septic patients, Kopterides et al. recommended 
microdialysis measurement only for research purposes due to insufficient studies in this patient population16. 
Additionally, it is known that microdialysis16 as well as CGM systems17 differ in relation to the stage and type of 
sepsis, which might exacerbate obtaining a precise interstitial glucose measurement.
Fundamentally, a comparison of surgical and medical patients is of interest as both groups differ in various 
aspects that may alter interstitial glucose sensor performance (e.g. catheter-related bloodstream infections, altera-
tions in microvascular blood flow)18,19. Recommendations for glucose treatment in ICU patients are not specified 
for surgical and medical patients2 and in addition it is still not yet investigated whether different types of critical 
illnesses have different effects on the accuracy of a microdialysis-based CGM signal. Furthermore, it needs to be 
proven if the time point of calibration influences the quality of the measurement compared to reference values. 
The aim of the present study was to investigate the accuracy of continuous subcutaneous glucose monitoring by 
means of microdialysis in two different critically ill patient populations (surgical patients after major cardiac sur-
gery (SICU group) and medical patients with severe sepsis (MICU group) and to investigate whether the prolon-
gation of the run-in period improves the signal quality. As a working hypothesis, we expected stable perfusion of 
the probe after introduction of a 6-hour run-in period, reflected by an improvement in the subcutaneous glucose 
signal in both patient populations.
Methods
The current study comprises data from two trials (14–189 ex 03/04; 16–233 ex 04/05), which were performed in 
two populations including overall 30 critically ill patients (Table 1): 20 patients at the surgical intensive care unit 
after major cardiac surgery (SICU group) and 10 patients at the medical intensive care unit with severe sepsis 
(MICU group). The SICU group was treated at the Department of Cardiothoracic Surgery and MICU group was 
treated at the Department of Internal Medicine, both at the Medical University of Graz, Austria. These studies 
were mono-centric, non-controlled prospective observational experiments. The study protocols were approved 
before the year 2010 by the local ethics committee of the Medical University of Graz, Austria, and therefore not 
registered in a clinical trial registry. Both studies were performed according to Good Clinical Practice (GCP) and 
the Declaration of Helsinki. Patients were treated according to the best practice and no other study related inter-
vention was performed. Nutrition management was performed according to local standards. Patients received 
enteral nutrition via tube with a flow rate of 50–80 ml/h from 8:00 AM to 6:00 AM the following day. Parenteral 
nutrition was administered continuously aiming at 20–25 kcal/kg bodyweight; septic patients received 50% more 
than patients without sepsis. In the MICU group, patients were under mechanical ventilation; written informed 
consent was obtained from the closest relative before starting study related activities. SICU patients gave their 
written informed consent before the elective cardio-thoracic surgery and prior to any trial related activities.
Preparation. In all 30 patients, standard subcutaneous microdialysis for glucose measurement was applied. 
The sampling period was up to 24 hours in the MICU group and up to 48 hours in the SICU group. In both patient 
SICU (n = 20) MICU (n = 10)
Age (years) 69 ± 7 57 ± 11
Ethnicity (Caucasian) 20 10
Female gender (n) 5 (25%) 5 (50%)
BMI (kg/m2) 28 ± 5 35 ± 15
History of diabetes (n) 6 (30%) 2 (20%)
APACHE II score 10 ± 3 31 ± 4
Table 1. Subject characteristics. BMI = body mass index, SICU = surgical patients after major cardiac surgery, 
MICU = medical patients with severe sepsis. Values are given as mean and SD. APACHE II score = Acute 
physiology and chronic health evaluation.
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groups, a CMA 60 (CMA Microdialysis AB, Solna, Sweden) microdialysis probe (membrane cut-off: 20 kDa, 
30 × 0.6 mm) was inserted into the subcutaneous adipose tissue of the abdominal region. Using a portable micro-
pump (CMA 107; CMA Microdialysis AB, Solna, Sweden), the isotonic perfusion solution (5% mannitol) was 
transported through the catheter at a constant flow rate of 1 µl/min. Dialysate samples were collected in micro-
tubes and tubes were changed every 60 min over the whole study period. A graphical illustration of the microdial-
ysis principle is depicted in the supplemental material. Simultaneously, arterial blood samples were withdrawn to 
measure blood glucose reference concentrations every 60 min. Dialysate samples were immediately deep frozen 
(−80 °C) and later analysed for glucose concentrations using a Cobas Mira Analyzer (Hoffmann-La Roche, Basel, 
Switzerland) and for sodium concentrations using a flame photometer (Instrumentation Laboratory, Vienna, 
Austria) at the laboratory of Joanneum Research GmbH, Graz, Austria. Reference blood glucose concentrations 
were measured immediately at site using a blood gas analyser (Omni S, Roche Diagnostics, Basel, Switzerland). 
Blood glucose reference readings were used for prospectively calibrating the microdialysis signal. Intrarun (inter-
run) coefficients of variation were 1.3% (1.6%) and 0.4% (0.4%) for glucose and sodium, respectively.
The measured glucose concentration in subcutaneous dialysate was calibrated via two- steps: firstly, using an 
ionic reference technique to calculate actual subcutaneous glucose concentration and secondly, using a one-point 
calibration to obtain a glucose profile comparable to arterial blood glucose4. The ionic reference calibration 
accounts for a lower measured dialysate glucose concentration in relation to the actual subcutaneous glucose 
concentration and is calculated for each sample using the following equation: actual subcutaneous glucose con-
centration = dialysate glucose x plasma sodium/dialysate sodium. As both plasma and tissue sodium concentra-
tions can be considered relatively constant, fluctuations in dialysate sodium can be attributed mainly to effects 
at the site of the microdialysis membrane (SIUC dialysate sodium: 103.6 ± 17.7 mmol/l, SICU plasma sodium: 
141.2 ± 2.93 mmol/l; MICU dialysate sodium: 111.9 ± 23.0 mmol/l, MICU plasma sodium: 139.1 ± 6.34 mmol/l). 
Actual subcutaneous glucose concentration, as calculated using the ionic reference technique, is lower compared 
with the actual arterial blood glucose concentration. Therefore, as a second calibration step, actual subcutaneous 
glucose concentration was calibrated to blood glucose using a one-point calibration procedure. Using this pro-
cedure, the ratio between the first actual subcutaneous glucose concentration reading and the average of the two 
corresponding blood glucose readings was used to calculate actual subcutaneous glucose concentration-derived 
blood glucose.
The calibration procedure was performed as previously described4 using the ionic reference technique to 
account for sodium recovery and then prospectively calibrating the subcutaneous signal to blood concentrations. 
Calibration was conducted as a one-point calibration either one or six hours after insertion of the microdialysis 
catheter. All laboratory analyses were performed according to Good Laboratory Practice (GLP).
Data analysis. Data were tested for distribution via D’Agostino & Pearson omnibus normality test. Normally 
distributed data were expressed as mean ± standard deviation (SD) and non-normally distributed data were 
expressed as median and 25–75 percentiles. Comparison of standard subcutaneous microdialysis for glucose 
measurement with the corresponding arterial glucose concentration was performed via Wilcoxon matched-pairs 
signed rank test with a significance level of p < 0.05 for both groups. Paired reference – microdialysis values were 
used to calculate median difference, median absolute difference (MAD) and median absolute relative difference 
(MARD). MARD for the comparison of calibration 1 hour versus 6 hours after catheter insertion was also per-
formed by Wilcoxon matched-pairs signed rank test with a significance level of p < 0.05 for both groups.
Subcutaneous microdialysis samples were collected over a predefined time period of 60 minutes. To account 
for the long sampling interval of one hour, the reference blood glucose measurements corresponding to a start 
and an end glucose value of the interstitial samples were averaged and then paired with the according interstitial 
glucose value, as described previously20. Bland-Altman plot was used to indicate the relative differences between 
the paired glucose readings on the y-axis in relation to the average blood glucose concentration on the x-axis21,22.
The Clarke Error Grid analysis23 was applied to clinically evaluate the data. Five zones characterise errors of 
varying levels of clinical significance, among which values in zones A and B are defined as clinically acceptable, 
whereas values in zones C, D or E are considered as potentially unsafe. The insulin titration error grid was used as 
described previously by Ellmerer et al.4.
Analyses were performed using SPSS 19 for Windows (SPSS, Chicago, IL, USA) and Microsoft Office Excel 
2010.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
Thirty critically ill patients were included in the analysis. Mean study duration was 37 hours in the SICU group 
and 26 hours in the MICU group.
In total, we obtained 596 paired glucose readings from the SICU group and 220 from the MICU group. For 
the SICU group, calibrating the microdialysis signal 1 hour after catheter insertion resulted in a prospectively cal-
ibrated glucose concentration of 6.7 (5.7; 8.3) mmol/l versus a reference value of 6.3 (5.5; 7.8) mmol/l (p < 0.001). 
For the MICU group, 1 hour post-catheter insertion calibrated subcutaneous glucose concentration was found at 
8.2 (7.1; 9.9) mmol/l versus a reference value of 7.9 (6.9; 9.3) mmol/l (p = 0.014).
When accounting for a 6-hour run-in period, prospectively calibrated glucose concentration was found at 5.9 
(5.2; 7.5) mmol/l in comparison to a reference arterial blood value of 6.1 (5.4; 7.5) mmol/l for the SICU group 
(p = 0.012). For the MICU group, glucose concentration calibrated at hour 6 was found at 8.1 (6.5; 10.0) mmol/l 
versus a reference arterial blood value of 7.9 (7.0; 9.3) mmol/l (p = 0.014).
www.nature.com/scientificreports/
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Recovery rates for interstitial glucose (73 ± 10% SICUh1, 74 ± 10% SICUh6, 82 ± 12 MICUh1, 82 ± 12 MICUh6) 
and CV of recovery (1.5% SICUh1, 1.4% SICUh6, 3.4% MICUh1, 3.4% MICUh6) were comparable between groups.
Overall levels for median difference, MAD and MARD for both calibration time-points are given in Table 2. 
When comparing MARD of the glucose signal calibrated at 1 hour versus 6 hours after catheter insertion, a sig-
nificant improvement in signal quality was found in patients after major cardiac surgery (p < 0.001). In patients 
with severe sepsis, introduction of a 6-hours run-in period after catheter insertion did not result in a significant 
improvement in the sensor quality assessed by MARD (p = 0.11).
The mean glucose differences (2 SD) between subcutaneous and reference glucose was 6.8 (47.8) % for SICU 
group and −18.8 (128.2) % for MICU group when calibrated 1 hour after catheter insertion. When calibrated at hour 
6 after catheter insertion 2 SD were found at −2.2 (39.3) % (SICU group) and −7.2 (65.6) % (MICU group) (Fig. 1).
SICUh1 MICUh1 SICUh6 MICUh6
MedDiff (mmol/l) 0.33 (−0.11; 0.87) 0.11 (−0.57; 1.09) −0.06 (−0.44; 0.33) 2.89 (−0.59; 1.37)
MAD (mmol/l) 0.61 (0.27; 1.22) 0.88 (0.38; 1.75) 0.38 (0.16; 0.84) 0.88 (0.35; 1.83)
MARD (%) 9.9 (4.2; 17.9) 11.8 (5.0; 22.3) 6.2 (2.6; 12.4) 11.1 (4.8; 22.9)
Table 2. Median difference (MedDiff), median absolute difference (MAD) and median absolute relative 
difference (MARD) for group MICU and SICU calibrated 1 hour (MICUh1 and SICUh1) and 6 hours (MICUh6 
and SICUh6) after catheter insertion. Values are given as median and 25–75 percentiles.
Figure 1. Mean glucose differences (2 SD) between interstitial and reference blood glucose concentrations. 
A = SICU calibrated after 1 h, B = SICU calibrated after 6 h, C = MICU calibrated after 1 h and D = MICU 
calibrated after 6 h.
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Clarke Error Grid analysis showed that 99.3% of the glucose values for SICU calibrated 1 hour after catheter 
insertion were in zones A and B (80.4% A, 18.9% B), whereas 4 values (0.7%) were located in zone C. For the 
MICU group, the glucose signal calibrated 1 hour after catheter insertion gave following results: 89.1% of the 
values were within zones A and B (71.4% A, 17.7% B), 9.9% were located in zone C, and one value was located in 
zones D and E, respectively. Calibration at hour 6 showed the following results for SICU: 87.9% in zone A, 11.7% 
in zone B and 0.4% in zone C; for MICU: 72.4% in zone A, 26.4% in zone B, 0.6% in zone C and 0.6% in zone E, 
respectively (Fig. 2).
Discussion
CGM data from critically ill patients are scarce and clearly differ from results observed in patients with diabetes 
due to altered tissue perfusion24.
In a recent prospective study in critically ill patients assessing the performance of a continuous intravenous 
microdialysis-based glucose-monitoring device, trend accuracy was found to be very good. In contrast, point 
accuracy was only moderate to good, translating to neglect a threshold of 95% of paired values in zone A of the 
Clarke error grid25, which is similar to the findings in our study. In a different setting during surgery in ICU 
patients, a disagreement between subcutaneous and intravenous continuous glucose monitoring was found26. In 
this study the mean venous glucose level was 125 ± 29 mg/dl versus a subcutaneous glucose level of 138 ± 26 mg/
dl26. Additionally, it has to be taken into account that the sensor function was found in previous research to be 
impaired by blood clots close to the sensor application site27. Blood injections, proximal to the sensor, caused 
lowered sensor glucose values and temporary signal reductions.
Figure 2. Clarke Error Grid analysis for A = SICU calibration 1 hour after catheter insertion, B = SICU 
calibration 6 hours after catheter insertion, C = MICU calibration 1 hour after catheter insertion, D = SICU 
calibration 6 hours after catheter insertion.
www.nature.com/scientificreports/
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Contrary to the findings of Lorencio et al.17 our findings demonstrate considerable influence of the type of 
critically ill patient (medical or surgical) on the accuracy of the subcutaneous signal. Especially in patients with 
sepsis, the disease per se reduces the potential of the CGM device to measure glucose accurately. Both alterations 
in microvascular blood flow and decrease in density of small vessels were found to be present in patients with 
sepsis19. Further, different inflammatory mediators potentially decrease microvascular blood flow and increased 
endothelin leads to exaggerated microvascular vasoconstriction28. As stated by Martinez and colleagues29, metab-
olism in patients with sepsis differ markedly from that associated with circulatory failure, which might influence 
sensor accuracy.
In patients after cardiac surgery, it was found that CGM sensors had acceptable accuracy30. The microcircu-
lation was impaired to a limited extent compared with that in patients with sepsis and healthy controls, although 
this impairment was not related to sensor accuracy. These findings are in line with our results from the SICU 
group, in which superior accuracy was observed compared to the MICU group, and prolongation of the run-in 
period up to 6 hours post-catheter insertion resulted in an improved sensor signal.
Although an offset was found when comparing subcutaneous and arterial blood glucose values, the subcu-
taneous signal could follow trends in blood glucose adequately in both groups. MARD for calibration at hour 1 
was in both groups similar to microdialysis results seen in a previous study in patients with diabetes and could 
even outperform these results when introducing a 6-h run-in period in the SICU but not in the MICU group20. 
Clarke Error Grid Analysis also supports these findings: for SICU there was an increase in the number of values 
laying in zone A after introduction of the 6 hours run-in period (80.4 vs. 87.9%). Although there was also a trend 
of improved performance for the MICU group after introduction of the 6-hour run-in period, this result was 
only seen in zone B (17.7% vs. 26.4%), whereas numbers in the clinical accurate zone A did not change (71.4% vs. 
72.4%). These results from the SICU group are similar to data observed in patients with diabetes20. In contrast to 
vascular microdialysis in critically ill patients, performance of subcutaneous microdialysis was worse and could 
also not reach comparable accuracy after introduction of a 6 hours run-in period15. Interestingly, our data, in line 
with previously published data on vascular microdialysis15, are close to the MARD of 10%, which is requested in 
diabetes care to enable non-adjunct continuous subcutaneous glucose monitoring for insulin dosing decisions 
and also fulfils criteria proposed for critical care (MARD < 14%)31.
A recent study clearly demonstrated the agreement of a point-of-care device when compared to laboratory 
assays in critically ill patients32. Bias, limits of agreement and coefficients of correlation were found for glucose at 
−0.8 (−1.4 to −0.2 g/dl, r = 0.985), which is below CLIA cut-off values. The accuracy of the point-of-care devices, 
as used in our study, supports the accuracy to initiate therapy without waiting for central laboratory measure-
ments. However, we used the ionic reference technique for micro-dialysis recovery rates-correction which is 
accompanied with electrolyte-free perfusate. These sodium concentrations were analysed by a flame photome-
ter (sample by sample); Unfortunately, real-time monitoring was not possible using this setting. However, fur-
ther developments of this technique do allow real-time monitoring of the dialysates by infrared spectrometry. 
Vahlsing et al. used either acetate or mannitol as recovery marker added to the perfusate and marker losses, as 
determined by infrared spectrometry33,34.
When interpreting the data, it has to be taken into account that the results provided are based on two indi-
vidual study protocols using an identical study design but a different sample size (n = 10 for MICU vs. n = 20 
for SICU). As the aim of this comparison was to investigate whether different clinical conditions (septic state 
vs. elective cardiothoracic surgery) influence the subcutaneous signal, anthropometric parameters such as body 
composition (body mass index, BMI) do not match. There might be a different pattern of adipose tissue blood 
flow between lean and obese patients, which could also affect signal accuracy. Furthermore, this study is limited 
by its small patient cohort and the lack of a healthy control group.
Further studies need to investigate the accuracy of vascular and subcutaneous glucose monitoring systems 
in different groups of critically ill patients, leading to a deeper understanding of illness-dependent effects on the 
glucose monitoring. Furthermore, the effects of different illness states and body constitutions on CGM accuracy 
are not yet sufficiently investigated in critically ill patients.
Conclusions
This study investigated the accuracy of a standard subcutaneous microdialysis technique for glucose monitoring 
in critically ill surgical patients after major cardiac surgery and in medical patients with severe sepsis. We con-
clude that the prolongation of a run-in period up to 6 hours results in an improvement of subcutaneous signal 
accuracy in patients after major cardiac surgery, but not in patients with severe sepsis, possibly due to altered 
tissue perfusion in the septic state. From a clinical point of view, it must be taken into account that standard sub-
cutaneous microdialysis technique for glucose monitoring might not be adequate to obtain accurate glucose pro-
files in patients with severe sepsis. This inaccuracy cannot be ameliorated by a prolongation of the run-in period.
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